AAIC 2022 and Biomarkers View overview page

What do we understand about the secretion of brain p-tau in AD?

Next steps in VCID research: molecular targets and fluid biomarkers

Blood p-tau in symptomatic and non-symptomatic AD patients

Association between synaptic biomarkers of AD and brain function and structure

Importance of standardizing biomarker protocols in the diagnosis of AD

Neuronal network hyperexcitability as a biomarker in Alzheimer’s disease

The five domains of mild behavioral impairment

MBI associated with decreased connectivity in networks linked with Alzheimer’s disease

Impact of Alzheimer’s disease treatments on apathy

Is there a genetic basis for the rate of progression of Alzheimer’s disease?

What is the relationship between COVID-19 and Alzheimer’s disease?

Modifiable dementia risk factors associated with higher CSF tau and poorer cognition in middle age

The prodromal phases of Alzheimer’s disease

CSF tau as a biomarker of therapeutic effect

Early predictive value of plasma biomarkers for amyloid positivity

Biomarkers in dementia with Lewy bodies: αSyn RT-QuIC